Abstract
The first lines of defense in the human innate immune system are membrane receptors called Toll-like receptors (TLRs). This family of receptors functions as primary sensors to recognize microbial pathogens. Subsequent binding of ligands to TLRs lend to the activation of cellular signaling pathways that regulate expression of genes related to inflammation and immunity. The discovery and supporting evidence of functional and structural diversity suggests TLRs are key participants in cellular immunity and are important to various medical conditions including the tumor microenvironment. TLR heterogeneity emphasizes the role of these receptors and suggests a new opportunity to develop therapies targeting specific or multiple TLRs that may contribute to the treatment of a myriad of diseases including various cancers. In this article, we intend to focus on a number of recently issued patents related to TLRs and to propose the relevance of these patents to novel treatments for cancers.
Keywords: Toll-like receptors, cancer, innate immunity, immunology
Recent Patents on Anti-Cancer Drug Discovery
Title: Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer
Volume: 4 Issue: 3
Author(s): Kevin Kimbro and Sabrenia Parker
Affiliation:
Keywords: Toll-like receptors, cancer, innate immunity, immunology
Abstract: The first lines of defense in the human innate immune system are membrane receptors called Toll-like receptors (TLRs). This family of receptors functions as primary sensors to recognize microbial pathogens. Subsequent binding of ligands to TLRs lend to the activation of cellular signaling pathways that regulate expression of genes related to inflammation and immunity. The discovery and supporting evidence of functional and structural diversity suggests TLRs are key participants in cellular immunity and are important to various medical conditions including the tumor microenvironment. TLR heterogeneity emphasizes the role of these receptors and suggests a new opportunity to develop therapies targeting specific or multiple TLRs that may contribute to the treatment of a myriad of diseases including various cancers. In this article, we intend to focus on a number of recently issued patents related to TLRs and to propose the relevance of these patents to novel treatments for cancers.
Export Options
About this article
Cite this article as:
Kimbro Kevin and Parker Sabrenia, Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (3) . https://dx.doi.org/10.2174/157489209789206904
DOI https://dx.doi.org/10.2174/157489209789206904 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plant Derived Inhibitor Sulforaphane in Combinatorial Therapy Against Therapeutically Challenging Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry The Molecular Pathology of Eye Tumors: A 2019 Update Main Interests for Routine Clinical Practice
Current Molecular Medicine Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry Vesicles: A Recently Developed Novel Carrier for Enhanced Topical Drug Delivery
Current Drug Delivery Multitarget Drugs of Plants Origin Acting on Alzheimer's Disease
Current Medicinal Chemistry Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry Cytokine Network: New Targeted Therapy for Pancreatic Cancer
Current Pharmaceutical Design Targeted Delivery of Natural Bioactives and Lipid-nanocargos against Signaling Pathways Involved in Skin Cancer
Current Medicinal Chemistry Gold- and Silver-based Nano-Particles Influence Pseudo-Typed Lenti-viral Infection
Current Nanoscience Approaches to Gastrointestinal Cytoprotection: From Isolated Cells, Via Animal Experiments to Healthy Human Subjects and Patients with Different Gastrointestinal Disorders
Current Pharmaceutical Design Inhalable Antibiotic Nanoformulations for the Treatment of Pseudomonas Aeruginosa Infection in Cystic Fibrosis – A Review
Drug Delivery Letters Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets Targeting Trail Towards the Clinic
Current Drug Targets Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium
Current Alzheimer Research Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery